Condition: Hepatitis B, Chronic (CHB) · Sponsor: Ausper Biopharma Co., Ltd.
The study adopts an open-label, multiple-dose design and aims to evaluate the efficacy and safety of AHB-171 Injection after multiple doses in treatment-naïve (HBeAg-negative/positive) and nucleos(t)ide analogue (NA)-treated (HBeAg-negative) participants with chronic hepatitis B (CHB)
This description comes directly from the study's public registry record.
Bella Lu · 0571-86959519 · clinicaltrial@ausperbio.com
Always discuss trial participation with your own doctor first.
| AusperBio Investigational Site | Beijing, Beijing Municipality, China | Recruiting |
| AusperBio Investigational Site | Chongqing, Chongqing Municipality, China | Recruiting |
| AusperBio Investigational Site | Xiamen, Fujian, China | Recruiting |
| AusperBio Investigational Site | Guangzhou, Guangdong, China | Recruiting |
| AusperBio Investigational Site | Nanning, Guangxi, China | Recruiting |
| AusperBio Investigational Site | Zhengzhou, Henan, China | Recruiting |
| AusperBio Investigational Site | Changzhou, Jiangsu, China | Recruiting |
| AusperBio Investigational Site | Jilin City, Jilin, China | Recruiting |
| AusperBio Investigational Site | Chengdu, Sichuang, China | Recruiting |
| AusperBio Investigational Site | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07630727